Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, +166

The Lancet

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Anas Younes, Laurie H. Sehn, Peter Johnson, +27

Journal of Clinical Oncology

Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial

Nagesh Kalakonda, Marie Maerevoet, Federica Cavallo, +34

The Lancet Haematology

Hematological MalignancyLymphoid NeoplasiaMedicineHematologyPathology +2

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada, +203

The Lancet Oncology

Lymphoid NeoplasiaEnd-of-induction Pet ResponseMedicinePrognostic ValueFollicular Lymphoma +5

Serum albumin level at diagnosis of diffuse large B‐cell lymphoma: an important simple prognostic factor

Osnat Bairey, Adi Shacham‐Abulafia, Ofer Shpilberg, +1

Hematological Oncology

ImmunohematologyImmunodeficienciesPrognosisImmunologyDiagnosis +18

Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study

Ron Ram, Odelia Amit, Tsila Zuckerman, +5

Annals of Hematology

Hematological MalignancyMedicineImmunologyHematologyPharmacotherapy +2

Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients – a matched control multicenter cohort study

Ron Ram, Sigal Grisariu, Liat Shargian, +14

Haematologica

Clinical ImmunologyElderly PatientsImmunodeficienciesYounger PatientsImmunology +19

Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies

Ronit Gurion, Uri Rozovski, Gilad Itchaki, +14

Haematologica

ImmunodeficienciesHumoral ResponseImmunologyPathologyImmunodominance +14

Central nervous system involvement in T-cell lymphoma: A single center experience

Ronit Gurion, Neha Mehta, Jocelyn Migliacci, +6

Acta Oncologica

ImmunologyPathologyImmunotherapyHematological MalignancyNeuro-oncology +16

Risk factors for high‐dose methotrexate associated acute kidney injury in patients with hematological malignancies

Irina Amitai, Uri Rozovski, Reem El‐Saleh, +6

Hematological Oncology